Journal article
Impact of concurrent angiotensin inhibitors on outcomes with PD1/L1 inhibitors for patients (pts) with metastatic urothelial carcinoma (mUC).
Abstract
e17044
Background: Preclinical data indicate that angiotensin inhibition may improve drug delivery by enhancing tumor perfusion partly by downregulating transforming growth factor (TGF)-β. Since (TGF)-β appears to be associated with resistance in patients with mUC receiving PD1/L1 inhibitors, we investigated whether angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) may enhance the …
Authors
Curran C; Pond GR; Nuzzo PV; Abou Alaiwi S; Nassar A; Wei XX; Kilbridge KL; McGregor BA; Ravi P; Ravi A
Journal
Journal of Clinical Oncology, Vol. 38, No. 15_suppl, pp. e17044–e17044
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2020
DOI
10.1200/jco.2020.38.15_suppl.e17044
ISSN
0732-183X